Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure by Paul G. Richardson, Marcie L. Riches, Nancy A. Kernan, Joel A. Brochstein, Shin Mineishi, Amanda M. Termuhlen, Sally Arai, Stephan A. Grupp, Eva C. Guinan, Paul L. Martin, Gideon Steinbach, Amrita Krishnan, Eneida R. Nemecek, Sergio Giralt, Tulio Rodriguez, Reggie Duerst, John Doyle, Joseph H. Antin, Angela Smith, Leslie Lehmann, Richard Champlin, Alfred Gillio, Rajinder Bajwa, Ralph B. D’Agostino, Joseph Massaro, Diane Warren, Maja Miloslavsky, Robin L. Hume, Massimo Iacobelli, Bijan Nejadnik, Alison L. Hannah, and Robert J. Soiffer Blood Volume 127(13):1656-1665 March 31, 2016 ©2016 by American Society of Hematology Participant flow in the defibrotide group. Paul G. Richardson et al. Blood 2016;127:1656-1665 ©2016 by American Society of Hematology Participant flow in the historical-control group. Paul G. Richardson et al. Blood 2016;127:1656-1665 ©2016 by American Society of Hematology Kaplan–Meier estimate. Paul G. Richardson et al. Blood 2016;127:1656-1665 ©2016 by American Society of Hematology